Find Clinical Trial

A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.


← Back
Study Phase

Phase 3

Therapeutic Area

Other

Active substance/
Medical device

GEVOKIZUMAB, S078989

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS078989
Protocol CodeCL3-78989-019
EudraCT Code2013-004973-29
NCT CodeNCT02375685


Documents and links

Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility